Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma.
Gohara S, Shinohara K, Yoshida R, Kariya R, Tazawa H, Hashimoto M, Inoue J, Kubo R, Nakashima H, Arita H, Kawaguchi S, Yamana K, Nagao Y, Iwamoto A, Sakata J, Matsuoka Y, Takeshita H, Hirayama M, Kawahara K, Nagata M, Hirosue A, Kuwahara Y, Fukumoto M, Okada S, Urata Y, Fujiwara T, Nakayama H. Gohara S, et al. Among authors: tazawa h. Mol Ther Oncolytics. 2022 Oct 8;27:141-156. doi: 10.1016/j.omto.2022.10.001. eCollection 2022 Dec 15. Mol Ther Oncolytics. 2022. PMID: 36381653 Free PMC article.
Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y, Tazawa H, Yamada M, Kanaya N, Fushimi T, Kikuchi S, Kuroda S, Ohara T, Noma K, Yoshida R, Umeda Y, Urata Y, Kagawa S, Fujiwara T. Kajiwara Y, et al. Among authors: tazawa h. Cancer Immunol Immunother. 2023 May;72(5):1285-1300. doi: 10.1007/s00262-022-03334-x. Epub 2022 Nov 27. Cancer Immunol Immunother. 2023. PMID: 36436021 Free PMC article.
Dual-targeted near-infrared photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in the tumor microenvironment.
Sato H, Noma K, Ohara T, Kawasaki K, Akai M, Kobayashi T, Nishiwaki N, Narusaka T, Komoto S, Kashima H, Katsura Y, Kato T, Kikuchi S, Tazawa H, Kagawa S, Shirakawa Y, Kobayashi H, Fujiwara T. Sato H, et al. Among authors: tazawa h. Sci Rep. 2022 Nov 23;12(1):20152. doi: 10.1038/s41598-022-24313-3. Sci Rep. 2022. PMID: 36418422 Free PMC article.
ADAR1 is a promising risk stratification biomarker of remnant liver recurrence after hepatic metastasectomy for colorectal cancer.
Hata N, Shigeyasu K, Umeda Y, Yano S, Takeda S, Yoshida K, Fuji T, Yoshida R, Yasui K, Umeda H, Takahashi T, Kondo Y, Kishimoto H, Mori Y, Teraishi F, Yamamoto H, Michiue H, Nakamura K, Tazawa H, Fujiwara T. Hata N, et al. Among authors: tazawa h. Sci Rep. 2023 Feb 6;13(1):2078. doi: 10.1038/s41598-023-29397-z. Sci Rep. 2023. PMID: 36747029 Free PMC article.
Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody.
Nishiwaki N, Noma K, Ohara T, Kunitomo T, Kawasaki K, Akai M, Kobayashi T, Narusaka T, Kashima H, Sato H, Komoto S, Kato T, Maeda N, Kikuchi S, Tanabe S, Tazawa H, Shirakawa Y, Fujiwara T. Nishiwaki N, et al. Among authors: tazawa h. Cancer Immunol Immunother. 2023 Jul;72(7):2029-2044. doi: 10.1007/s00262-023-03378-7. Epub 2023 Feb 10. Cancer Immunol Immunother. 2023. PMID: 36764954 Free PMC article.
Dual antiplatelet therapy inhibits neutrophil extracellular traps to reduce liver micrometastases of intrahepatic cholangiocarcinoma.
Yoshimoto M, Kagawa S, Kajioka H, Taniguchi A, Kuroda S, Kikuchi S, Kakiuchi Y, Yagi T, Nogi S, Teraishi F, Shigeyasu K, Yoshida R, Umeda Y, Noma K, Tazawa H, Fujiwara T. Yoshimoto M, et al. Among authors: tazawa h. Cancer Lett. 2023 Jul 28;567:216260. doi: 10.1016/j.canlet.2023.216260. Epub 2023 Jun 7. Cancer Lett. 2023. PMID: 37295551
398 results